Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anticancer application of 2-methoxy estradiol, Neomycin sulfate and their mixture

A technology of methoxyestradiol and neomycin sulfate, which is applied in the field of cancer treatment, and can solve the problems of no drugs that effectively inhibit tumor growth and/or treat tumors.

Inactive Publication Date: 2003-11-05
上海福缘生化药学研发有限公司
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] However, so far, there are no drugs in the art that effectively inhibit tumor growth and / or treat tumors, especially drugs that work by effectively inhibiting angiogenesis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anticancer application of 2-methoxy estradiol, Neomycin sulfate and their mixture
  • Anticancer application of 2-methoxy estradiol, Neomycin sulfate and their mixture
  • Anticancer application of 2-methoxy estradiol, Neomycin sulfate and their mixture

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] acquisition of materials

[0054] The sources of materials used in the present invention are as follows. Human angiogenin was prepared or purchased by conventional recombinant ribonucleic acid methods. Basic and acidic fibroblast growth factors (bFGF and aFGF) were purchased from Promega Company of the United States; special medium for vascular endothelial cells (HE-SFM) was purchased from Gibco / BRL Company of the United States. Estradiol, 2-methoxyestradiol, and neomycin sulfate were purchased from Sigma, USA. Human placental venous vascular endothelial cells (HUVE) were purchased from Cell Systems, USA; human colon adenocarcinoma cell HT29, human prostate cancer cell PC3, human cervical cancer cell HeLa, human glioma cell SW1088, human breast cancer cell MCF7 and human liver cancer cell HepG2 were purchased from ATCC in the United States; cancer cell culture medium DMEM and fetal bovine serum (FBS) were purchased from Biowhittaker in the United States. The immunode...

Embodiment 2

[0056] cell culture

[0057] Human placental venous vascular endothelial cells (HUVE) were cultured in special medium for vascular endothelial cells (HE-SFM+10%FCS+10ng / mlbFGF) containing 10% fetal bovine serum and 10 ng / ml basic fibroblast growth factor middle. The culture conditions are constant temperature and humidity at 37 degrees Celsius and 5% carbon dioxide gas phase. The medium was changed every two days, and the culture medium was subcultured at a ratio of 1:3. HUVE cells from passage 3 to passage 15 were used for experiments.

[0058] Human colon adenocarcinoma cell HT29, human prostate cancer cell PC3, human cervical cancer cell HeLa, human glioma cell SW1088, human breast cancer cell MCF7 and human liver cancer cell HepG2 were cultured in DMEM containing 10% fetal bovine serum. Subculture at a ratio of 1:4.

Embodiment 3

[0060] Neomycin sulfate inhibits the nuclear transfer of angiogenin and basic and acidic fibroblast growth factors in vascular endothelial cells

[0061] Vascular endothelial cells are the main cells that make up blood vessels and are also the target cells of many angiogenic factors. Under the stimulation of angiogenic factors, these cells migrate, divide, and recombine to form the embryonic form of new blood vessels. Angiogenic factors including angiogenin and basic and acidic fibroblast growth factors must enter the nucleus of vascular endothelial cells to perform their functions. This example proves that neomycin sulfate can effectively inhibit the nuclear transfer of angiogenin and basic and acidic fibroblast growth factors.

[0062] HUVE cells were treated with trypsin-EDTA, the number of cells was determined with a hemocytometer or a Coulter counter, and then cultured in a 35-mm cell culture dish at a density of 5,000 cells per square centimeter. After 24 hours, wash t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides the application of 2-methoxy estradiol, Neomycin sulfate and their mixture in inhibiting the nuclear translocation of angiogenesis factor. Animal test shows that each of 2-methoxy estradiol and Neomycin sulfate can inhibit the growth of human tumor cell in nude mouse and the mixture of them has even high effect. The present invention also provides the medicine composition containing 2-methoxy estradiol and Neomycin sulfate.

Description

technical field [0001] The present invention relates to the field of cancer treatment. Specifically, the present invention relates to a new drug for inhibiting angiogenesis and thereby inhibiting the growth and metastasis of cancer cells. More specifically, the present invention discloses that 2-methoxyestradiol and neomycin sulfate can be used to inhibit the process of nuclear transfer of angiogenic factors to reduce the formation of new blood vessels. Background technique [0002] The dependence of tumor growth and metastasis on angiogenesis has been widely accepted by the scientific community. Tumor tissue can only grow to a size of 1-2 mm in diameter unless it establishes its own vascular network. Tumors of this size do not pose a hazard to the human body. At present, a widely concerned and accepted theory is that long-term use of drugs that inhibit angiogenesis can keep tumor cells in the latent period. In this way, cancer, like high blood pressure and diabetes, can...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7034A61P35/00
Inventor 胡国富
Owner 上海福缘生化药学研发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com